It was reported that knocking out TCR, a typical strategy for generating universal CAR-T, could abate CD19.CAR-T tonic signaling and CAR-T persistence,48 whereas improving tonic signaling could benefit CD22.CAR-T function and clinical efficacy.6 Given the lack of a convenient system for modulating CAR-T tonic signaling strength, our novel approach of introducing PCPs on the CAR surface has critical implications for the clinical translation of CAR-T therapy against hematologic malignancies. The gene discussed is CD19; the disease is hematologic disorder.